Ann Agric Environ Med:哮喘、鼻炎和湿疹与对乙酰氨基酚使用的相关性分析

2018-10-13 AlexYang MedSci原创

对乙酰氨基酚是一种常见的儿童使用药物,越来越多的流行病学研究表明对乙酰氨基酚的使用可能是哮喘、过敏性鼻炎和特应性湿疹的风险因子。最近,有研究人员确定和鉴定了对乙酰氨基酚的使用与哮喘、过敏性鼻炎和特应性湿疹症状之间的相关性。研究包括了6-7岁的儿童(n=4510)、13-14岁的青少年(n=4721)和20-44岁的成年人(n=9386),分别占比 24.2%, 25.4%和50.4%。研究发现,乙

对乙酰氨基酚是一种常见的儿童使用药物,越来越多的流行病学研究表明对乙酰氨基酚的使用可能是哮喘、过敏性鼻炎和特应性湿疹的风险因子。最近,有研究人员确定和鉴定了对乙酰氨基酚的使用与哮喘、过敏性鼻炎和特应性湿疹症状之间的相关性。

研究包括了6-7岁的儿童(n=4510)、13-14岁的青少年(n=4721)和20-44岁的成年人(n=9386),分别占比 24.2%, 25.4%和50.4%。研究发现,乙酰氨基酚的使用在所有评估的年龄组中都具有明显的剂量依赖的哮喘症状风险的增加。研究人员利用风险比(OR)来对发展的哮喘症状进行了阐述,哮喘症状包括了6-7岁组中气喘和胸中喘息、13-14岁组和成年人组的锻炼引起的呼吸急促,具体依据过去12个月乙酰氨基酚的使用频率,并且与过去12个月期间没有使用乙酰氨基酚的对照组进行了比较。研究发现,通过风险比数据分析,过去12个月乙酰氨基酚的使用与鼻炎的风险和皮肤过敏症症状风险具有明显的相关性,并且是剂量依赖的方式。

最后,研究人员指出,乙酰氨基酚的使用应该是哮喘、鼻炎和皮肤过敏的一个风险因子。

原始出处:

Lipiec A, Wawrzyniak ZM, Sybilski AJ et al. The association between paracetamol use and the risk of asthma, rhinitis and eczema in the Polish population. Ann Agric Environ Med. 25 Sep 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=371325, encodeId=ee013e13259b, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ffb2116260, createdName=wlqjhfs, createdTime=Thu Aug 15 22:19:34 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952066, encodeId=560819520667f, content=<a href='/topic/show?id=3dbb2346632' target=_blank style='color:#2F92EE;'>#乙酰氨基酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23466, encryptionId=3dbb2346632, topicName=乙酰氨基酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Wed Jan 23 05:46:00 CST 2019, time=2019-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837577, encodeId=b3e6183e577ff, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Jun 24 03:46:00 CST 2019, time=2019-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349542, encodeId=579c349542ee, content=吃饭刚刚还好还好哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Tue Oct 16 17:52:57 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349415, encodeId=095c34941590, content=沟沟壑壑刚刚干活, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Mon Oct 15 13:04:11 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321791, encodeId=25f71321e91ed, content=<a href='/topic/show?id=818246618a4' target=_blank style='color:#2F92EE;'>#对乙酰氨基酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46618, encryptionId=818246618a4, topicName=对乙酰氨基酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afdf491, createdName=lilili1104, createdTime=Mon Oct 15 09:46:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523611, encodeId=42f1152361113, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Mon Oct 15 09:46:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524270, encodeId=ce2715242e036, content=<a href='/topic/show?id=053710045ad' target=_blank style='color:#2F92EE;'>#iron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10045, encryptionId=053710045ad, topicName=iron)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f1b11597510, createdName=july_979, createdTime=Mon Oct 15 09:46:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609187, encodeId=18d0160918eac, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Oct 15 09:46:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349203, encodeId=725b34920324, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat Oct 13 19:39:12 CST 2018, time=2018-10-13, status=1, ipAttribution=)]
    2019-08-15 wlqjhfs

    不错

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=371325, encodeId=ee013e13259b, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ffb2116260, createdName=wlqjhfs, createdTime=Thu Aug 15 22:19:34 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952066, encodeId=560819520667f, content=<a href='/topic/show?id=3dbb2346632' target=_blank style='color:#2F92EE;'>#乙酰氨基酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23466, encryptionId=3dbb2346632, topicName=乙酰氨基酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Wed Jan 23 05:46:00 CST 2019, time=2019-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837577, encodeId=b3e6183e577ff, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Jun 24 03:46:00 CST 2019, time=2019-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349542, encodeId=579c349542ee, content=吃饭刚刚还好还好哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Tue Oct 16 17:52:57 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349415, encodeId=095c34941590, content=沟沟壑壑刚刚干活, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Mon Oct 15 13:04:11 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321791, encodeId=25f71321e91ed, content=<a href='/topic/show?id=818246618a4' target=_blank style='color:#2F92EE;'>#对乙酰氨基酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46618, encryptionId=818246618a4, topicName=对乙酰氨基酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afdf491, createdName=lilili1104, createdTime=Mon Oct 15 09:46:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523611, encodeId=42f1152361113, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Mon Oct 15 09:46:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524270, encodeId=ce2715242e036, content=<a href='/topic/show?id=053710045ad' target=_blank style='color:#2F92EE;'>#iron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10045, encryptionId=053710045ad, topicName=iron)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f1b11597510, createdName=july_979, createdTime=Mon Oct 15 09:46:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609187, encodeId=18d0160918eac, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Oct 15 09:46:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349203, encodeId=725b34920324, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat Oct 13 19:39:12 CST 2018, time=2018-10-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=371325, encodeId=ee013e13259b, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ffb2116260, createdName=wlqjhfs, createdTime=Thu Aug 15 22:19:34 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952066, encodeId=560819520667f, content=<a href='/topic/show?id=3dbb2346632' target=_blank style='color:#2F92EE;'>#乙酰氨基酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23466, encryptionId=3dbb2346632, topicName=乙酰氨基酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Wed Jan 23 05:46:00 CST 2019, time=2019-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837577, encodeId=b3e6183e577ff, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Jun 24 03:46:00 CST 2019, time=2019-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349542, encodeId=579c349542ee, content=吃饭刚刚还好还好哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Tue Oct 16 17:52:57 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349415, encodeId=095c34941590, content=沟沟壑壑刚刚干活, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Mon Oct 15 13:04:11 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321791, encodeId=25f71321e91ed, content=<a href='/topic/show?id=818246618a4' target=_blank style='color:#2F92EE;'>#对乙酰氨基酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46618, encryptionId=818246618a4, topicName=对乙酰氨基酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afdf491, createdName=lilili1104, createdTime=Mon Oct 15 09:46:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523611, encodeId=42f1152361113, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Mon Oct 15 09:46:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524270, encodeId=ce2715242e036, content=<a href='/topic/show?id=053710045ad' target=_blank style='color:#2F92EE;'>#iron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10045, encryptionId=053710045ad, topicName=iron)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f1b11597510, createdName=july_979, createdTime=Mon Oct 15 09:46:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609187, encodeId=18d0160918eac, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Oct 15 09:46:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349203, encodeId=725b34920324, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat Oct 13 19:39:12 CST 2018, time=2018-10-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=371325, encodeId=ee013e13259b, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ffb2116260, createdName=wlqjhfs, createdTime=Thu Aug 15 22:19:34 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952066, encodeId=560819520667f, content=<a href='/topic/show?id=3dbb2346632' target=_blank style='color:#2F92EE;'>#乙酰氨基酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23466, encryptionId=3dbb2346632, topicName=乙酰氨基酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Wed Jan 23 05:46:00 CST 2019, time=2019-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837577, encodeId=b3e6183e577ff, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Jun 24 03:46:00 CST 2019, time=2019-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349542, encodeId=579c349542ee, content=吃饭刚刚还好还好哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Tue Oct 16 17:52:57 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349415, encodeId=095c34941590, content=沟沟壑壑刚刚干活, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Mon Oct 15 13:04:11 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321791, encodeId=25f71321e91ed, content=<a href='/topic/show?id=818246618a4' target=_blank style='color:#2F92EE;'>#对乙酰氨基酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46618, encryptionId=818246618a4, topicName=对乙酰氨基酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afdf491, createdName=lilili1104, createdTime=Mon Oct 15 09:46:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523611, encodeId=42f1152361113, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Mon Oct 15 09:46:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524270, encodeId=ce2715242e036, content=<a href='/topic/show?id=053710045ad' target=_blank style='color:#2F92EE;'>#iron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10045, encryptionId=053710045ad, topicName=iron)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f1b11597510, createdName=july_979, createdTime=Mon Oct 15 09:46:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609187, encodeId=18d0160918eac, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Oct 15 09:46:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349203, encodeId=725b34920324, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat Oct 13 19:39:12 CST 2018, time=2018-10-13, status=1, ipAttribution=)]
    2018-10-16 为你把脉

    吃饭刚刚还好还好哈

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=371325, encodeId=ee013e13259b, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ffb2116260, createdName=wlqjhfs, createdTime=Thu Aug 15 22:19:34 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952066, encodeId=560819520667f, content=<a href='/topic/show?id=3dbb2346632' target=_blank style='color:#2F92EE;'>#乙酰氨基酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23466, encryptionId=3dbb2346632, topicName=乙酰氨基酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Wed Jan 23 05:46:00 CST 2019, time=2019-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837577, encodeId=b3e6183e577ff, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Jun 24 03:46:00 CST 2019, time=2019-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349542, encodeId=579c349542ee, content=吃饭刚刚还好还好哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Tue Oct 16 17:52:57 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349415, encodeId=095c34941590, content=沟沟壑壑刚刚干活, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Mon Oct 15 13:04:11 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321791, encodeId=25f71321e91ed, content=<a href='/topic/show?id=818246618a4' target=_blank style='color:#2F92EE;'>#对乙酰氨基酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46618, encryptionId=818246618a4, topicName=对乙酰氨基酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afdf491, createdName=lilili1104, createdTime=Mon Oct 15 09:46:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523611, encodeId=42f1152361113, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Mon Oct 15 09:46:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524270, encodeId=ce2715242e036, content=<a href='/topic/show?id=053710045ad' target=_blank style='color:#2F92EE;'>#iron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10045, encryptionId=053710045ad, topicName=iron)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f1b11597510, createdName=july_979, createdTime=Mon Oct 15 09:46:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609187, encodeId=18d0160918eac, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Oct 15 09:46:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349203, encodeId=725b34920324, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat Oct 13 19:39:12 CST 2018, time=2018-10-13, status=1, ipAttribution=)]
    2018-10-15 为你把脉

    沟沟壑壑刚刚干活

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=371325, encodeId=ee013e13259b, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ffb2116260, createdName=wlqjhfs, createdTime=Thu Aug 15 22:19:34 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952066, encodeId=560819520667f, content=<a href='/topic/show?id=3dbb2346632' target=_blank style='color:#2F92EE;'>#乙酰氨基酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23466, encryptionId=3dbb2346632, topicName=乙酰氨基酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Wed Jan 23 05:46:00 CST 2019, time=2019-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837577, encodeId=b3e6183e577ff, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Jun 24 03:46:00 CST 2019, time=2019-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349542, encodeId=579c349542ee, content=吃饭刚刚还好还好哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Tue Oct 16 17:52:57 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349415, encodeId=095c34941590, content=沟沟壑壑刚刚干活, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Mon Oct 15 13:04:11 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321791, encodeId=25f71321e91ed, content=<a href='/topic/show?id=818246618a4' target=_blank style='color:#2F92EE;'>#对乙酰氨基酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46618, encryptionId=818246618a4, topicName=对乙酰氨基酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afdf491, createdName=lilili1104, createdTime=Mon Oct 15 09:46:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523611, encodeId=42f1152361113, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Mon Oct 15 09:46:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524270, encodeId=ce2715242e036, content=<a href='/topic/show?id=053710045ad' target=_blank style='color:#2F92EE;'>#iron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10045, encryptionId=053710045ad, topicName=iron)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f1b11597510, createdName=july_979, createdTime=Mon Oct 15 09:46:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609187, encodeId=18d0160918eac, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Oct 15 09:46:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349203, encodeId=725b34920324, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat Oct 13 19:39:12 CST 2018, time=2018-10-13, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=371325, encodeId=ee013e13259b, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ffb2116260, createdName=wlqjhfs, createdTime=Thu Aug 15 22:19:34 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952066, encodeId=560819520667f, content=<a href='/topic/show?id=3dbb2346632' target=_blank style='color:#2F92EE;'>#乙酰氨基酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23466, encryptionId=3dbb2346632, topicName=乙酰氨基酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Wed Jan 23 05:46:00 CST 2019, time=2019-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837577, encodeId=b3e6183e577ff, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Jun 24 03:46:00 CST 2019, time=2019-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349542, encodeId=579c349542ee, content=吃饭刚刚还好还好哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Tue Oct 16 17:52:57 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349415, encodeId=095c34941590, content=沟沟壑壑刚刚干活, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Mon Oct 15 13:04:11 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321791, encodeId=25f71321e91ed, content=<a href='/topic/show?id=818246618a4' target=_blank style='color:#2F92EE;'>#对乙酰氨基酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46618, encryptionId=818246618a4, topicName=对乙酰氨基酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afdf491, createdName=lilili1104, createdTime=Mon Oct 15 09:46:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523611, encodeId=42f1152361113, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Mon Oct 15 09:46:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524270, encodeId=ce2715242e036, content=<a href='/topic/show?id=053710045ad' target=_blank style='color:#2F92EE;'>#iron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10045, encryptionId=053710045ad, topicName=iron)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f1b11597510, createdName=july_979, createdTime=Mon Oct 15 09:46:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609187, encodeId=18d0160918eac, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Oct 15 09:46:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349203, encodeId=725b34920324, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat Oct 13 19:39:12 CST 2018, time=2018-10-13, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=371325, encodeId=ee013e13259b, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ffb2116260, createdName=wlqjhfs, createdTime=Thu Aug 15 22:19:34 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952066, encodeId=560819520667f, content=<a href='/topic/show?id=3dbb2346632' target=_blank style='color:#2F92EE;'>#乙酰氨基酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23466, encryptionId=3dbb2346632, topicName=乙酰氨基酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Wed Jan 23 05:46:00 CST 2019, time=2019-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837577, encodeId=b3e6183e577ff, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Jun 24 03:46:00 CST 2019, time=2019-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349542, encodeId=579c349542ee, content=吃饭刚刚还好还好哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Tue Oct 16 17:52:57 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349415, encodeId=095c34941590, content=沟沟壑壑刚刚干活, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Mon Oct 15 13:04:11 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321791, encodeId=25f71321e91ed, content=<a href='/topic/show?id=818246618a4' target=_blank style='color:#2F92EE;'>#对乙酰氨基酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46618, encryptionId=818246618a4, topicName=对乙酰氨基酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afdf491, createdName=lilili1104, createdTime=Mon Oct 15 09:46:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523611, encodeId=42f1152361113, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Mon Oct 15 09:46:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524270, encodeId=ce2715242e036, content=<a href='/topic/show?id=053710045ad' target=_blank style='color:#2F92EE;'>#iron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10045, encryptionId=053710045ad, topicName=iron)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f1b11597510, createdName=july_979, createdTime=Mon Oct 15 09:46:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609187, encodeId=18d0160918eac, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Oct 15 09:46:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349203, encodeId=725b34920324, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat Oct 13 19:39:12 CST 2018, time=2018-10-13, status=1, ipAttribution=)]
    2018-10-15 july_979
  9. [GetPortalCommentsPageByObjectIdResponse(id=371325, encodeId=ee013e13259b, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ffb2116260, createdName=wlqjhfs, createdTime=Thu Aug 15 22:19:34 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952066, encodeId=560819520667f, content=<a href='/topic/show?id=3dbb2346632' target=_blank style='color:#2F92EE;'>#乙酰氨基酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23466, encryptionId=3dbb2346632, topicName=乙酰氨基酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Wed Jan 23 05:46:00 CST 2019, time=2019-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837577, encodeId=b3e6183e577ff, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Jun 24 03:46:00 CST 2019, time=2019-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349542, encodeId=579c349542ee, content=吃饭刚刚还好还好哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Tue Oct 16 17:52:57 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349415, encodeId=095c34941590, content=沟沟壑壑刚刚干活, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Mon Oct 15 13:04:11 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321791, encodeId=25f71321e91ed, content=<a href='/topic/show?id=818246618a4' target=_blank style='color:#2F92EE;'>#对乙酰氨基酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46618, encryptionId=818246618a4, topicName=对乙酰氨基酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afdf491, createdName=lilili1104, createdTime=Mon Oct 15 09:46:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523611, encodeId=42f1152361113, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Mon Oct 15 09:46:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524270, encodeId=ce2715242e036, content=<a href='/topic/show?id=053710045ad' target=_blank style='color:#2F92EE;'>#iron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10045, encryptionId=053710045ad, topicName=iron)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f1b11597510, createdName=july_979, createdTime=Mon Oct 15 09:46:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609187, encodeId=18d0160918eac, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Oct 15 09:46:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349203, encodeId=725b34920324, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat Oct 13 19:39:12 CST 2018, time=2018-10-13, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=371325, encodeId=ee013e13259b, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ffb2116260, createdName=wlqjhfs, createdTime=Thu Aug 15 22:19:34 CST 2019, time=2019-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952066, encodeId=560819520667f, content=<a href='/topic/show?id=3dbb2346632' target=_blank style='color:#2F92EE;'>#乙酰氨基酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23466, encryptionId=3dbb2346632, topicName=乙酰氨基酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Wed Jan 23 05:46:00 CST 2019, time=2019-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837577, encodeId=b3e6183e577ff, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Jun 24 03:46:00 CST 2019, time=2019-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349542, encodeId=579c349542ee, content=吃饭刚刚还好还好哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Tue Oct 16 17:52:57 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349415, encodeId=095c34941590, content=沟沟壑壑刚刚干活, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Mon Oct 15 13:04:11 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321791, encodeId=25f71321e91ed, content=<a href='/topic/show?id=818246618a4' target=_blank style='color:#2F92EE;'>#对乙酰氨基酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46618, encryptionId=818246618a4, topicName=对乙酰氨基酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afdf491, createdName=lilili1104, createdTime=Mon Oct 15 09:46:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523611, encodeId=42f1152361113, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Mon Oct 15 09:46:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524270, encodeId=ce2715242e036, content=<a href='/topic/show?id=053710045ad' target=_blank style='color:#2F92EE;'>#iron#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10045, encryptionId=053710045ad, topicName=iron)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f1b11597510, createdName=july_979, createdTime=Mon Oct 15 09:46:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609187, encodeId=18d0160918eac, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Oct 15 09:46:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349203, encodeId=725b34920324, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sat Oct 13 19:39:12 CST 2018, time=2018-10-13, status=1, ipAttribution=)]
    2018-10-13 天地飞扬

    了解一下,谢谢分享!

    0

相关资讯

盘点:鼻炎与治疗研究进展

【1】Curr Med Res Opin:一个大群体的舌下免疫治疗花费研究 在美国人口中,过敏性鼻炎(AR)影响的人数占比了高达40%,每年的医疗花费大约110亿美元。过敏免疫治疗是长期症状缓解的最好的选择,但是治疗依从性低。最近,有研究人员调查了那些接受全部免疫治疗和那些免疫治疗间断患者的舌下免疫治疗(SCIT)相关的花费情况。研究发现,与对照(n=394479)相比,SCIT(n

盘点:鼻部疾病研究进展

【1】Environ Pollut:大气中的粗细颗粒能够对鼻腔和支气管上皮细胞产生不同的影响和诱发不同的免疫响应大气中的颗粒物质(PM)在流行病学上能够加速恶化呼吸和免疫健康,包括过敏性鼻炎(AR)和支气管哮喘(BA)。尽管精细的和粗大的颗粒能够影响呼吸道,然而他们对上呼吸道和下呼吸道以及免疫系统的影响差异、它们潜在的机制和对健康造成不良影响的组成仍旧还没有完全的阐释。最近,有研究人员利用旋流

Laryngoscope:鼻用糖皮质激素不能导致眼部变化

鼻用糖皮质激素(INCS)的安全性和效果已经有了很好的评估,但是INCS仍具存在忧虑,即能够导致系统性的副作用,类似于口服类固醇。最近,有研究人员系统性的评估了是否INCS的使用能够增加眼内压(IOP)超过20mmHg、青光眼或者后囊下内障在鼻炎患者中的形成。研究总共包括了484个研究,其中有10个随机对照试验符合他们的标准。与安慰剂组对比,对2226名患者的元分析阐释了IOP提高的相对风险在那些

Expert Opin Pharmacother:苯磺酸贝托司汀在永久过敏性鼻炎中的治疗结果分析

苯磺酸贝托司汀(BB)是二代H1抗组胺药物,作为一种滴眼液,在美国是通过FDA批准的可以用于过敏性结膜炎治疗的药物。在其他的国家,口服BB是广泛存在的,主要是用于过敏性鼻炎(AR)以及荨麻疹和慢性瘙痒症状的改善,并且与其他药物治疗的结果类似。最近,有研究人员对文献进行了综合的搜索,这些文献的信息均来自临床试验。研究人员评估了BB的临床和非临床药理学情况,以及在AR中的使用和对症状的改善情况,还探究

PLoS One:小学儿童中,过敏相关的障碍(ARDs)研究

过敏性相关的障碍(ARDs)的流行度具有显著的增加,城市化被认为是ARDs发生的一个主要的环境风险因子,但是中低收入国家的相关数据有限。最近,有研究人员评估了ARDs和特应性反应在埃塞俄比亚乡村学生儿童群体中的流行度,并且鉴定了障碍的相关环境和生活方式因素。研究是一个代表性的研究,包括了541名学生儿童。研究参与者的女性占比60.3%,年龄为10-15岁。ARD的流行度为27%,曾经患有湿疹、鼻炎

NPJ Prim Care Respir Med:过敏性鼻炎治疗中关键影响因素鉴定分析

过敏性鼻炎(AR)越来越成为一种患者自身治疗的疾病。不多于70%的患者自己选择购买药物进行治疗,且没有专业人员的干预,其治疗结果总是令人不满意,这也导致了鼻炎不良治疗,增加了AR治疗对个人和社会的负担。然而,没有外部的影响也就没有上述情况的发生。最近,有研究人员确定了促使患者做出AR治疗决定的关键因素。为了达到上述目的,研究人员利用一个社交网络理论构架来描绘出患者的AR网络,并且在该网络中鉴定影响